Aller au contenu
Sommeil et rythmesEssai randomisé3 min read

Butyrate eased gut inflammation and improved sleep scores in 36 people with colitis

Collectif éditorial MoveVitals · Study published · Reading updated

Original paper:Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial. · Lipids in health and disease · 2024 · Article original ↗

À retenir

In 36 people with active ulcerative colitis, 12 weeks of sodium butyrate lowered faecal calprotectin and hs-CRP, raised several circadian-clock genes and improved the Pittsburgh Sleep Quality Index (PSQI) score versus placebo (all P < 0.001 for those outcomes). With only 36 participants and a short trial, the results need confirmation in larger studies.

Study design

Essai randomisé

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.

Question de recherche

In inflammatory bowel disease the body's circadian clock genes, which coordinate immune activity, are disturbed, and butyrate, a short-chain fatty acid made by gut bacteria, helps regulate both inflammation and these genes. The authors tested whether butyrate supplements would change clock-gene expression, inflammation, sleep and quality of life in active ulcerative colitis (UC).

Population et méthode

Double-blind randomized placebo-controlled trial of 36 people with active UC, who received sodium butyrate (600 mg/kg as stated in the abstract) or placebo for 12 weeks. Clock-gene expression (CRY1, CRY2, PER1, PER2, BMAL1, CLOCK) was measured in whole blood by qPCR and expressed as fold change from baseline. Faecal calprotectin and serum hs-CRP were measured by ELISA. Sleep quality used the Pittsburgh Sleep Quality Index (PSQI) and quality of life used the inflammatory bowel disease questionnaire-9 (IBDQ-9), before and after the intervention.

Résultats

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Compared with placebo, butyrate lowered faecal calprotectin (-133.82 ± 155.62 vs 51.58 ± 95.57, P < 0.001) and hs-CRP (-0.36 vs 0.48, P < 0.001).
  2. 2
    Butyrate raised the fold change in expression of CRY1 (2.22 ± 1.59 vs 0.63 ± 0.49, P < 0.001), CRY2 (2.15 ± 1.26 vs 0.93 ± 0.80, P = 0.001), PER1 (1.86 ± 1.77 vs 0.65 ± 0.48, P = 0.005) and BMAL1 (1.85 ± 0.97 vs 0.86 ± 0.63, P = 0.003).
  3. 3
    The PSQI score changed by -2.94 ± 3.50 with butyrate versus 1.16 ± 3.61 with placebo (P < 0.001); on the PSQI a lower score means better sleep.
  4. 4
    Quality of life on the IBDQ-9 changed by 17.00 ± 11.36 with butyrate versus -3.50 ± 6.87 with placebo (P < 0.001). The abstract reports no results for PER2 or CLOCK.

Limites et incertitude

  1. 1
    Only 36 patients took part over 12 weeks, so the trial is small and short, and it cannot show lasting effects or rare side effects.
  2. 2
    Sleep was measured by questionnaire rather than a sleep study or wearable, so changes reflect how patients felt they slept.
  3. 3
    Clock-gene expression was measured in whole blood, which may not reflect what happens in the gut.
  4. 4
    This reading is based on the abstract only, which does not say whether the groups were similar at baseline.

Mise en perspective

The results suggest butyrate may be worth studying further as an add-on in ulcerative colitis, but this single small trial is not enough to recommend a supplement. Anyone with ulcerative colitis should not start or change a treatment, supplement or dose without their gastroenterologist.

Vos données

Ulcerative colitis markers like calprotectin and CRP need lab tests. For sleep, a wearable can track sleep duration and consistency, though its estimates differ from the PSQI questionnaire. Keep the same device and compare your own multi-week trend, and share symptom and sleep changes with your clinician.

Comprendre ce type de preuve

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Résumé structuré des auteurs English

Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.

Background

The regulation of the circadian clock genes, which coordinate the activity of the immune system, is disturbed in inflammatory bowel disease (IBD). Emerging evidence suggests that butyrate, a short-chain fatty acid produced by the gut microbiota is involved in the regulation of inflammatory responses as well as circadian-clock genes. This study was conducted to investigate the effects of sodium-butyrate supplementation on the expression of circadian-clock genes, inflammation, sleep and life quality in active ulcerative colitis (UC) patients.

Methods

In the current randomized placebo-controlled trial, 36 active UC patients were randomly divided to receive sodium-butyrate (600 mg/kg) or placebo for 12-weeks. In this study the expression of circadian clock genes (CRY1, CRY2, PER1, PER2, BMAl1 and CLOCK) were assessed by real time polymerase chain reaction (qPCR) in whole blood. Gene expression changes were presented as fold changes in expression (2^-ΔΔCT) relative to the baseline. The faecal calprotectin and serum level of high-sensitivity C-reactive protein (hs-CRP) were assessed by enzyme-linked immunosorbent assay method (ELIZA). Moreover, the sleep quality and IBD quality of life (QoL) were assessed by Pittsburgh sleep quality index (PSQI) and inflammatory bowel disease questionnaire-9 (IBDQ-9) respectively before and after the intervention.

Results

The results showed that sodium-butyrate supplementation in comparison with placebo significantly decreased the level of calprotectin (-133.82 ± 155.62 vs. 51.58 ± 95.57, P-value < 0.001) and hs-CRP (-0.36 (-1.57, -0.05) vs. 0.48 (-0.09-4.77), P-value < 0.001) and upregulated the fold change expression of CRY1 (2.22 ± 1.59 vs. 0.63 ± 0.49, P-value < 0.001), CRY2 (2.15 ± 1.26 vs. 0.93 ± 0.80, P-value = 0.001), PER1 (1.86 ± 1.77 vs. 0.65 ± 0.48, P-value = 0.005), BMAL1 (1.85 ± 0.97 vs. 0.86 ± 0.63, P-value = 0.003). Also, sodium-butyrate caused an improvement in the sleep quality (PSQI score: -2.94 ± 3.50 vs. 1.16 ± 3.61, P-value < 0.001) and QoL (IBDQ-9: 17.00 ± 11.36 vs. -3.50 ± 6.87, P-value < 0.001).

Conclusion

Butyrate may be an effective adjunct treatment for active UC patients by reducing biomarkers of inflammation, upregulation of circadian-clock genes and improving sleep quality and QoL.

Sources et attribution

Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial.

Firoozi D, Masoumi SJ, Mohammad-Kazem Hosseini Asl S, Labbe A, Razeghian-Jahromi I, Fararouei M, Lankarani KB, Dara M.

Lipids in health and disease · 2024-07-13

DOI: 10.1186/s12944-024-02203-z ↗PubMed · 39003477 ↗Europe PMC · Licence indiquée: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée

Sources vérifiées 2026-11-01

Guides pratiques

À lire ensemble

·Méta-analyse d’essais

Exercise improved sleep-quality scores in adults 45 and older with sleep disorders

Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.

Journal of Exercise Science & Fitness

Explications approfondiesLire l’étude →
·Étude de cohorte

Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults

Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.

Sleep

Explications approfondiesLire l’étude →
·Essai randomisé

Sleep extension cut daily energy intake by about 270 kcal in adults with overweight

In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.

JAMA Internal Medicine

Explications approfondiesLire l’étude →
·Étude de cohorte

Six hours or less of sleep at 50 and 60 linked to higher dementia risk

In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.

Nature Communications

Explications approfondiesLire l’étude →
Sommeil et rythmes →